2022
Meta-analysis of molecular imaging of translocator protein in major depression
Eggerstorfer B, Kim JH, Cumming P, Lanzenberger R, Gryglewski G. Meta-analysis of molecular imaging of translocator protein in major depression. Frontiers In Molecular Neuroscience 2022, 15: 981442. PMID: 36226319, PMCID: PMC9549359, DOI: 10.3389/fnmol.2022.981442.Peer-Reviewed Original ResearchBody mass indexMajor depressive disorderMDD patientsMolecular imaging studiesTranslocator proteinImaging studiesTSPO availabilityPositron emission tomography studyMarkers of neuroinflammationSerotonin transporter availabilityEmission tomography studiesSystematic literature searchTime of scanningEffect sizeMolecular neuroimaging studiesMass indexDepressive disorderHealthy controlsMajor depressionTransporter availabilityHealthy subjectsTreatment statusDepression severityTemporal cortexBrain regionsBiodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1
Rischka L, Murgaš M, Pichler V, Vraka C, Rausch I, Winkler D, Nics L, Rasul S, Silberbauer LR, Reed MB, Godbersen GM, Unterholzner J, Handschuh P, Gryglewski G, Mindt T, Mitterhauser M, Hahn A, Ametamey SM, Wadsak W, Lanzenberger R, Hacker M. Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1. EJNMMI Research 2022, 12: 53. PMID: 36018389, PMCID: PMC9418393, DOI: 10.1186/s13550-022-00925-8.Peer-Reviewed Original ResearchExtrasynaptic NMDA receptorsStandardized uptake valueNMDA receptorsUrinary bladderEffective dose coefficientsPET radioligandNeuropsychiatric disordersTreatment monitoringSynaptic NMDA receptorsTime-integrated activity coefficientsCentral nervous systemUrinary bladder contentsDrug developmentDose coefficientsAdverse eventsExcitotoxic processTRIAL REGISTRATIONBladder contentsHealthy subjectsSynaptic transmissionSide effectsBone marrowNervous systemUptake valueEffective dose
2021
Coexpression of Gene Transcripts with Monoamine Oxidase A Quantified by Human In Vivo Positron Emission Tomography
Godbersen GM, Murgaš M, Gryglewski G, Klöbl M, Unterholzner J, Rischka L, Spies M, Baldinger-Melich P, Winkler D, Lanzenberger R. Coexpression of Gene Transcripts with Monoamine Oxidase A Quantified by Human In Vivo Positron Emission Tomography. Cerebral Cortex 2021, 32: 3516-3524. PMID: 34952543, DOI: 10.1093/cercor/bhab430.Peer-Reviewed Original ResearchConceptsExact testPositron emission tomography scanCerebral distribution volumeMonoamine oxidaseEmission tomography scanNovel therapeutic targetVivo positron emission tomographyFisher's exact testPositron emission tomographyFalse discovery rate correctionVivo MAOTomography scanHealthy subjectsSubcortical areasCortical areasTherapeutic targetMAOA expressionDistribution volumeEmission tomographyNeuropsychiatric disordersNeuron projectionsNeuron developmentNeuron differentiationSpearman's ρCell-cell signalingEscitalopram modulates learning content-specific neuroplasticity of functional brain networks
Klöbl M, Seiger R, Vanicek T, Handschuh P, Reed MB, Spurny-Dworak B, Ritter V, Godbersen GM, Gryglewski G, Kraus C, Hahn A, Lanzenberger R. Escitalopram modulates learning content-specific neuroplasticity of functional brain networks. NeuroImage 2021, 247: 118829. PMID: 34923134, DOI: 10.1016/j.neuroimage.2021.118829.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexSelective serotonin reuptake inhibitorsPrefrontal cortexBroca's areaLingual gyrusFunctional connectivityFunctional magnetic resonance imagingResting-state functional magnetic resonance imagingFunctional brain networksBrain functional connectivityFear extinctionComplexity of learningSerotonin reuptake inhibitorsHuman neuroplasticityBrain networksMagnetic resonance imagingEscitalopram intakeComparable modulationClinical improvementSSRI escitalopramDaily doseReuptake inhibitorsNeuroplastic changesHealthy subjectsNeuroplasticityEffects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm
Spurny B, Vanicek T, Seiger R, Reed MB, Klöbl M, Ritter V, Unterholzner J, Godbersen GM, Silberbauer LR, Pacher D, Klug S, Konadu ME, Gryglewski G, Trattnig S, Bogner W, Lanzenberger R. Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm. NeuroImage 2021, 232: 117913. PMID: 33657450, PMCID: PMC7610796, DOI: 10.1016/j.neuroimage.2021.117913.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsGamma-aminobutyric acidMajor depressive disorderSerotonin reuptake inhibitorsSSRI treatmentPlacebo administrationReuptake inhibitorsGlutamatergic functionGlutamatergic neurotransmissionDepressive disorderNeuroplastic effectsSerotonergic systemNeurotransmitter systemsHealthy subjectsPsychiatric disordersImpaired cognitive flexibilityBrain regionsNeurotransmitter concentrationsCognitive functionWidespread symptomsMemory formationLast dayDisordersDownstream effectsTreatment
2020
Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data
Unterholzner J, Gryglewski G, Philippe C, Seiger R, Pichler V, Godbersen GM, Berroterán-Infante N, Murgaš M, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. Cerebral Cortex 2020, 30: 3771-3780. PMID: 31989157, PMCID: PMC7232988, DOI: 10.1093/cercor/bhz341.Peer-Reviewed Original ResearchConceptsMRNA expressionRole of BDNFSerotonin 1A receptorEfficacy of drugsTreatment of disordersReceptor subtypesHealthy subjectsPsychiatric drugsBrain tissueCortical regionsVivo PETSerotonergic functioningViable targetDrugsSpearman's rhoCandidate gene transcriptsReceptorsCoexpression patternsRelative inaccessibility
2019
Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression
Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Translational Psychiatry 2019, 9: 5. PMID: 30664620, PMCID: PMC6341100, DOI: 10.1038/s41398-018-0308-2.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factor (BDNF) geneAffective disordersReceptor bindingSingle nucleotide polymorphismsPhenotype of depressionNeurotrophic factor geneSerotonin 1A receptor geneFunctional single nucleotide polymorphismsReceptor profileHealthy subjectsPET resultsRisk genotypesRs6265Multifactorial riskCortical regionsMixed modelsRisk allelesRs6295DisordersCortical surfaceReceptor geneReceptorsMolecular phenotypesHTR1ADepressionThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2018
Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI
Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. NeuroImage 2018, 181: 323-330. PMID: 29966719, DOI: 10.1016/j.neuroimage.2018.06.079.Peer-Reviewed Original ResearchConceptsFunctional MRIPercent signal changeTask-specific changesMotor cortexGlucose metabolismIpsilateral motor cortexImaging modalitiesSupplementary motor areaSecondary visual cortexHybrid PET/MRI scannerConstant infusion protocolTask-specific activationInfusion protocolDifferent activation patternsHealthy subjectsMotor areaArterial samplesCMRgluConstant infusionDifferent imaging modalitiesTracer uptakeVisual cortexSignificant associationUnspecific activationPET/MRI scanner
2017
Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Spies M, James GM, Berroterán-Infante N, Ibeschitz H, Kranz GS, Unterholzner J, Godbersen M, Gryglewski G, Hienert M, Jungwirth J, Pichler V, Reiter B, Silberbauer L, Winkler D, Mitterhauser M, Stimpfl T, Hacker M, Kasper S, Lanzenberger R. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. The International Journal Of Neuropsychopharmacology 2017, 21: 145-153. PMID: 29045739, PMCID: PMC5793827, DOI: 10.1093/ijnp/pyx085.Peer-Reviewed Original ResearchConceptsKetamine plasma levelsPositron emission tomographyAntidepressant effectsPlasma levelsSerotonin transporterEmission tomographyAntidepressant dosePositron emission tomography scanReal-life patient cohortEmission tomography scanHigh-dose ketamineSerotonin transporter bindingTest-retest variabilityWhole brain regionsAntidepressant dosesAntidepressant mechanismPatient cohortTomography scanSerotonergic systemTransporter bindingHealthy subjectsAnimal studiesHigh dosesKetamineAdministration
2016
Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG
Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vraka C, Sigurdardottir H, Vanicek T, James GM, Seiger R, Kautzky A, Silberbauer L, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG. Journal Of Nuclear Medicine 2016, 57: 1933-1940. PMID: 27390156, DOI: 10.2967/jnumed.116.176156.Peer-Reviewed Original ResearchConceptsBaseline glucose metabolismTask-specific changesGlucose metabolismTime-activity curvesConstant infusionBolus applicationF-FDGBlood samplingBaseline metabolismPatlak plotVenous blood samplesCerebral metabolic rateVenous blood samplingGeneral linear modelHigh intrasubject variabilityMultimodal brain imagingArterial blood samplingMotor cortexHealthy subjectsCMRgluRegional time-activity curvesRight thumbArterial samplesBlood samplesDefault mode regions
2015
Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding
Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015, 111: 505-512. PMID: 25652393, DOI: 10.1016/j.neuroimage.2015.01.049.Peer-Reviewed Original ResearchConceptsPositron emission tomographySerotonin transporterSerotonin releaseRespective projection areasReuptake of serotoninExtracellular serotonin concentrationBilateral parahippocampal gyrusComplex receptor interactionsProtein expression levelsProjection areaSerotonin 1ASerotonergic transmissionSerotonergic effectsSerotonin concentrationsSerotonergic toneRaphe regionSerotonergic neurotransmissionWhole-brain ANOVAReceptor expressionSerotonergic systemSerotonin systemGenotype statusHealthy subjectsSerotonergic structuresParahippocampal gyrus
2014
(S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling
Sladky R, Spies M, Hoffmann A, Kranz G, Hummer A, Gryglewski G, Lanzenberger R, Windischberger C, Kasper S. (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. NeuroImage 2014, 108: 243-250. PMID: 25536499, DOI: 10.1016/j.neuroimage.2014.12.044.Peer-Reviewed Original ResearchConceptsOrbitofrontal cortexDynamic causal modelingHealthy subjectsDouble-blind fMRI studyCortico-limbic circuitsMagnetic resonance imaging (MRI) scanningAmygdala activationDouble-blind designPharmaceutical treatment optionsFunctional magnetic resonance imaging (fMRI) scanningEmotional face discrimination taskAmygdala modulationNeurophysiologic functionTreatment optionsPsychiatric disordersModulatory effectsCitalopramFunctional MRI dataEscitalopramDiscrimination taskEffective connectivity methodsFMRI studyRegulatory effectsEffective connectivityDifferential effects